Mitochondrial drugs

Current Opinion in Chemical Biology

Volumn 12, Issue 4, 2008, Pages 457-463

  Toogood, Peter L ^a  

^a Lycera Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; 2 METHOXYESTRADIOL; ADENOSINE TRIPHOSPHATE; APOPTOLIDIN; ARSENIC TRIOXIDE; AUROVERTIN B; BENZODIAZEPINE DERIVATIVE; BZ 423; ELESCLOMOL; F16; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; OLIGOMYCIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; UNCLASSIFIED DRUG;

AGING; AUTOIMMUNE DISEASE; CANCER THERAPY; CELL DEATH; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; HOMEOSTASIS; IMMUNE FUNCTION TEST; IMMUNOPATHOLOGY; METABOLIC DISORDER; METABOLISM; MITOCHONDRIAL TOXICITY; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION REACTION; RESPIRATORY CHAIN; REVIEW; TARGET CELL;

ANIMALS; CELL MEMBRANE PERMEABILITY; DRUG TOXICITY; ELECTRON TRANSPORT; HUMANS; MITOCHONDRIA; PHARMACOLOGY; POROSITY;

MUS;

EID: 50449094619     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2008.06.002     Document Type: Review

References (67)

1. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39 (2005) 359-407
2. Letai A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8 (2008) 121-132
3. Nguyen D.M., and Hussain M. The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies. J Bioenerg Biomembr 39 (2007) 13-21
4. Gogvadze V., and Zhivotovsky B. Alteration of mitochondrial function and cell sensitization to death. J Bioenerg Biomembr 39 (2007) 23-30
5. Bouchier-Hayes L., Lartigue L., and Newmeyer D.D. Mitochondria: pharmacological manipulation of cell death. J Clin Invest 115 (2005) 2640-2647
6. Armstong J.S. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 151 (2007) 1154-1165. An excellent recent review of various approaches to targeting mitochondria for therapeutic benefit.
7. Hagland H., Nikolaisen J., Hodneland L.I., Gjertsen B.T., Bruserud O., and Tronstad K.J. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signaling. Expert Opin Therapeut Targets 11 (2007) 1055-1069
8. Galluzzi L., Larochette N., Zamzami N., and Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25 (2006) 4812-4830
9. Fantin V.R., and Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 25 (2006) 4787-4797
10. Dias N., and Bailly C. Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol 70 (2005) 1-12
11. Pedersen P.L. The cancer cell's 'power plants' as promising therapeutic targets: an overview. J Bioenerg Biomembr 39 (2007) 1-12
12. Adam-Vizi V., and Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci 27 (2006) 639-645
13. Fruehauf J.P., and Meyskens Jr. F.L. Reactive oxygen species: a breath of life or death?. Clin Cancer Res 13 (2007) 789-794
14. Kohanski M.A., Dwyer D.J., Hayete B., Lawrence C.A., and Collins J.J. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130 (2007) 797-810
15. -/- cells that are unable to undergo a metabolic conversion to glycolysis in response to inhibition of mitochondrial electron transport.
16. Neuzil J., Tomasetti M., Zhao Y., Dong L.F., Birringer M., Wang X.F., Low P., Wu K., Salvatore B.A., and Ralph S.J. Vitamin E analogs, a novel group of 'mitocans,' as anticancer agents: the importance of being redox-silent. Mol Pharmacol 71 (2007) 1185-1199
17. Neuzil J., Dyason J.C., Freeman R., Dong L.F., Prochazka L., Wang X.F., Scheffler I., and Ralph S.J. Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr 39 (2007) 65-72
18. Neuzil J., Wang X.F., Dong L.F., Low P., and Ralph S.J. Molecular mechanism of 'mitocan' -induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins. FEBS Lett 580 (2006) 5125-5129
19. Shiau C.W., Huang J.W., Wang D.S., Weng J.R., Yang C.C., Lin C.H., Li C., and Chen C.S. α-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function. J Biol Chem 281 (2006) 11819-11825
20. 1-ATPase. Chem Biol 8 (2001) 71-80
21. Daniel P.T., Koert U., and Schuppan J. Apoptolidin: induction of apoptosis by a natural product. Angew Chem Int Ed 45 (2006) 872-893
22. 1-ATPase inhibition and antiproliferative activity of apoptolidin analogues. Org Lett 8 (2006) 589-592
23. o-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423. Chem Biol 12 (2005) 485-496
24. 1-ATPase by resveratrol and related polyphenols. PNAS 104 (2007) 13632-13637
25. Cip1/Waf1 expression by induction of oxidative stress in human breast cancer cells. Cancer Res 66 (2006) 4880-48887
26. Gledhill J.R., and Walker J.E. Inhibitors of the catalytic domain of mitochondrial ATP synthase. Biochem Soc Trans 34 (2006) 989-992
27. 0-ATPase by ligands of the peripheral benzodiazepine receptor. Bioorg Med Chem Lett 17 (2007) 1667-1670
28. Blatt N.B., Bednarski J.J., Warner R.E., Leonetti F., Johnson K.M., Boitano A., Yung R., Richardson B.C., Johnson K.J., Ellman J.A., et al. Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility. J Clin Invest 110 (2002) 1123-1132
29. Bednarski J.J., Warner R.E., Rao T., Leonetti F., Yung R., Richardson B.C., Johnson K.J., Ellman J.A., Opipari Jr. A.W., and Glick G.D. Attenuation of autoimmune disease in Fas-deficient mice by treatment with a cytotoxic benzodiazepine. Arthritis Rheum 48 (2003) 757-766
30. Varani J., Bhagavathula N., Nerusu K.C., Sherzer H., Fay K., Boitano A.E., Glick G.D., Johnson K., Kang S., and Opipari Jr. A.W. A novel benzodiazepine selectively inhibits keratinocyte proliferation and reduces retinoid-induced epidermal hyperplasia in organ-cultured human skin. J Pharm Exp Therapeut 313 (2005) 56-63
31. Bhagavathula N., Nerusu K.C., Hanosh A., Aslam M.N., Sundberg T.B., Opipari Jr. A.W., Johnson K., Kang S., Glick G.D., and Varani J. 7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalene-2-ylmethyl)-3,4-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423) a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined immunodeficient mouse transplant model. J Pharmacol Exp Therapeut 324 (2008) 938-947
32. Sundberg T.B., Ney G.M., Subramanian C., Opipari Jr. A.W., and Glick G.D. The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-myc protein for rapid and specific degradation. Cancer Res 66 (2006) 1775-1782. The anti-proliferative effects of Bz-423 in B cells are mediated through a superoxide-dependent decrease in c-myc levels.
33. 0-ATPase. ACS Chem Biol 1 (2006) 304-308. A detailed mechanistic study establishing the kinetics of ATPase inhibition by this novel uncompetitive inhibitor.
34. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 (2006) 337-342
35. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Disc 5 (2006) 493-506
36. Buryanovskyy L., Fu Y., Boyd M., Ma Y., Hsieh T.C., Wu J.M., and Zhang Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 43 (2004) 11417-11426
37. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.-L., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 (2003) 191-196
38. Kaeberlein M., McDonagh T., Heltweg B., Hixon J., Westman E.A., Caldwell S.D., Napper A., Curtis R., DiStefano P.S., Fields S., et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280 (2005) 17038-17045
39. 0 ATP hydrolase. Bioorg Med Chem Lett 14 (2004) 1027-1030
40. 0 ATP hydrolase. Bioorg Med Chem Lett 14 (2004) 1031-1034
41. 0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors. J Med Chem 47 (2004) 1081-1084
42. Koul A., Dendouga N., Vergauwen K., Molenberghs B., Vranckx L., Willebrords R., Ristic Z., Lill H., Dorange I., Guillemont J., et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 3 (2007) 323-324
43. Chipuk J.E., Bouchier-Hayes L., and Green D.R. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ 13 (2006) 1396-1402
44. James M.L., Selleri S., and Kassiou M. Development of ligands for the peripheral benzodiazepine receptor. Curr Med Chem 13 (2006) 1991-2001
45. Veenman L., Papadopoulous V., and Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharmaceutical Des 13 (2007) 2385-2405
46. Yagoda N., von Rechenburg M., Zaganjor E., Bauer A.J., Yang W.S., Fridman D.J., Wolpaw A.J., Smukste I., Peltier J.M., Boniface J.J., et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447 (2007) 864-868. Erastin is selectively cytotoxic toward tumor cells harboring an oncogenic ras protein.
47. Dilda P.J., and Hogg P.J. Arsenical-based cancer drugs. Cancer Treatment Rev 33 (2007) 542-564
48. Berkenblit A., Eder Jr. J.P., Ryan D.P., Seiden M.V., Tatsuta N., Sherman M.L., Dahl T.A., Dezube B.J., and Supko J.G. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 13 (2007) 584-590. Elesclomol™ (formerly STA-4783) is a pro-oxidant drug with clinical activity against metastatic melanoma.
49. Huang P., Feng L., Oldham E.A., Keating M.J., and Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407 (2000) 390-395
50. Balaban R.S., Nemoto S., and Finkel T. Mitochondria, oxidants, and aging. Cell 120 (2005) 483-495
51. Houstis N., Rosen E.D., and Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
52. Nadanaciva S., Bernal A., Aggeler R., Capaldi R., and Will Y. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Tox In Vitro 21 (2007) 902-911
53. Lewis W., Day B.J., and Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nature 2 (2003) 812-822
54. Dykens J.A., and Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Disc Today 12 (2007) 777-785
55. Rossignol R., Faustin B., Rocher C., Malgat M., Mazat J.P., and Letellier T. Mitochondrial threshold effects. Biochem J 370 (2003) 751-762
56. Ramanathan A., Wang C., and Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A 102 (2005) 5992-5997. An analysis of the bioenergetic states of progressively transformed cells links cancer causing genes to an increasing dependence on glycolysis.
57. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., and Thompson C.B. The Biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7 (2008) 11-20. A summary of metabolic changes associated with tumorigenesis including an increase in aerobic glycolysis.
58. Jones R.G., and Thompson C.B. Revving the engine: signal transduction fuels T cell activation. Cell Immunity 27 (2007) 173-178
59. Fox C.J., Hammerman P.S., and Thompson C.B. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 5 (2005) 844-852
60. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., Keating M.J., and Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278 (2003) 37832-37839
61. Yi J., Gao F., Shi G., Li H., Wang Z., Shi X., and Tang X. The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 7 (2002) 209-215
62. Schumacher P.T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10 (2006) 175-176
63. Wagner B.K., Kitami T., Gilbert T.J., Peck D., Ramanathan A., Schreiber S.L., Golub T.R., and Mootha V.K. Large-scale chemical dissection of mitochondrial function. Nat Biotech 26 (2008) 343-351. High throughput screens of cell viability, mitochondrial physiology, and gene expression are used to interrogate mitochondrial biology and toxicity as well as to identify novel therapeutics.
64. Huang T.C., Chang H.Y., Hsu C.H., Kuo W.H., Chang K.J., and Juan H.F. Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J Proteome Res (2008) 10.1021/pr700742h
65. Yamada Y., Akita H., Kogure K., Kamiya H., and Harashima H. Mitochondrial drug delivery and mitochondrial disease therapy-an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 7 (2007) 63-71
66. Nishii T., Suzuki S., Yoshida K., Arakaki K., and Tsunoda T. Total synthesis of the (+)-antimycin A3 family; structure elucidation of (+)-antimycin A3a. Tetrahedron Lett 44 (2003) 7829-7832
67. Palmer R.A., and Potter B.S. X-Ray structures and absolute configurations of the antibiotics oligomycins A, B and C: inhibitors of ATP synthase. J Chem Cryst 38 (2008) 243-253